Clinical Trial

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-07; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Recruiting 2025-05-06
Trial Details
NCT Number NCT06680752
Lead Sponsor ARCE Therapeutics, Inc.
Conditions Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, MDS (Myelodysplastic Syndrome)
Enrollment 49 participants
Start Date 2025-05-20
Primary Completion 2028-10 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-10